Publicacions en col·laboració amb investigadors/es de Universidad Politécnica de Valencia (35)

2024

  1. Impact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study

    Pharmaceutics, Vol. 16, Núm. 6

  2. Integrating Mechanistic and Toxicokinetic Information in Predictive Models of Cholestasis

    Journal of Chemical Information and Modeling, Vol. 64, Núm. 7, pp. 2775-2788

  3. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model

    Biomedicine and Pharmacotherapy, Vol. 170

  4. Phys-DAT: A physiologically-based pharmacokinetic model for unraveling the dissolution, transit and absorption processes using PhysPK®

    Computer Methods and Programs in Biomedicine, Vol. 243

  5. Population Pharmacokinetic–Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats

    Pharmaceutics, Vol. 16, Núm. 8

  6. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. Alternative Pharmacokinetic Metrics in Single-Dose Studies to Ensure Bioequivalence of Prolonged-Release Products at Steady State—A Case Study

    Pharmaceutics, Vol. 15, Núm. 2

  2. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 9, pp. 2691-2702

  3. Commonly used methods for dissolution profile comparison

    Time-Proof Perspectives on Bioequivalence (Nova Science Publishers, Inc.), pp. 297-322

  4. Correction: A Review of Population Pharmacokinetic Analyses of Linezolid (Clinical Pharmacokinetics, (2022), 61, 6, (789-817), 10.1007/s40262-022-01125-2)

    Clinical Pharmacokinetics

  5. Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union

    Pharmaceutics, Vol. 15, Núm. 2

  6. Usage of model combination in computational toxicology

    Toxicology Letters, Vol. 389, pp. 34-44

2022

  1. A Review of Population Pharmacokinetic Analyses of Linezolid

    Clinical Pharmacokinetics, Vol. 61, Núm. 6, pp. 789-817

  2. Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series

    Pharmaceutics, Vol. 14, Núm. 5

  3. Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis

    Pharmaceutics, Vol. 14, Núm. 3

  4. Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics

    European Journal of Pharmaceutical Sciences, Vol. 174

2021

  1. Estimators and confidence intervals of f2 using bootstrap methodology for the comparison of dissolution profiles

    Computer Methods and Programs in Biomedicine, Vol. 212

  2. Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations

    British Journal of Clinical Pharmacology, Vol. 87, Núm. 3, pp. 905-915

  3. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7

  4. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20